Navigation Links
AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
Date:3/14/2008

PASADENA, Calif., March 14 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $56,000, or break even per share basic and diluted, for the three months ended December 31, 2007, compared with a net profit of $36,000, or break even per share basic and diluted, for the three months ended December 31, 2006. For the year ended December 31, 2007, the net loss was $118,000, or $0.01 per share basic and diluted, compared with net loss of $481,000, or $0.03 per share basic and diluted for the same period in 2006. As of December 31, 2007, the Company reported $8.8 million in cash and marketable securities, the same amount reported as of December 31, 2006.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales at Colloral LLC, our joint venture with Deseret Laboratories, Inc., were up from the third quarter, but results were down compared to the fourth quarter of last year. The response to marketing through The Shopping Channel in Canada is encouraging." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46 "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug MBP8298, if it reaches the market. BioMS recently reported that it signed a licensing and development agreement with Eli Lilly and Company granting them exclusive worldwide rights to MBP8298. AutoImmune's rights to payments and royalties are unchanged by this new agreement. Dr. Bishop remarked, "It is comforting to see Eli Lilly and Company make this commitment to commercializing MBP8298. Should the product be successful in ongoing Phase III trials, Lilly's regulatory, marketing and sales capabilities will be of great value in capitalizing on this opportunity."

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

This release contains forward-looking statements that involve risks and uncertainties. The Company's actual results may differ significantly from results discussed in the forward-looking statements due to a number of important factors, including, but not limited to the uncertainties of clinical trial results, the Company's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed in the Company's most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section "Risk Factors." The discussion in the Annual Report on Form 10-KSB is hereby referenced into this release.

- Financial Chart Follows -

AUTOIMMUNE INC.

STATEMENT OF OPERATIONS

(Unaudited)

Three months ended Year ended

December 31, December 31,

2006 2007 2006 2007

Revenue $137,000 $75,000 $401,000 $294,000

Costs and expenses:

Cost of product revenue 28,000 1,000 46,000 21,000

Research and development 45,000 49,000 217,000 144,000

Selling, general and

administrative 152,000 181,000 1,058,000 713,000

Total costs and

expenses 225,000 231,000 1,321,000 878,000

Interest income 113,000 105,000 428,000 440,000

Minority interest in

joint venture 11,000 (5,000) 11,000 1,000

Other income - - - 25,000

124,000 100,000 439,000 466,000

Net loss $36,000 ($56,000) ($481,000) ($118,000)

Net loss per share -

basic $0.00 ($0.00) ($0.03) ($0.01)

Net loss per share -

diluted $0.00 ($0.00) ($0.03) ($0.01)

Weighted average common

shares outstanding -

basic 16,919,623 16,979,623 16,919,623 16,970,558

Weighted average common

shares outstanding -

diluted 16,919,623 16,979,623 16,919,623 16,970,558

CONDENSED BALANCE SHEET

(Unaudited)

December 31, December 31,

2006 2007

Cash and marketable securities $8,763,000 $8,819,000

Other current assets 188,000 152,000

Total assets $8,951,000 $8,971,000

Current liabilities $128,000 $128,000

Minority interest in joint venture - 11,000

Total stockholders' equity 8,823,000 8,832,000

Total liabilities and equity $8,951,000 $8,971,000


'/>"/>
SOURCE AutoImmune Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
2. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... (PRWEB) , ... August 29, 2020 , ... ... new Animal Nutrition manufacturing capability in Wuxi, China. The new plant operation will ... quality standards and advanced technology. , “This facility will improve the flexibility ...
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society announced ... Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on ... consortium of academic research centers in the United States and Europe with expertise ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a ... has closed on the purchase of greenfield for a new, expanded manufacturing facility. ... over 21 acres in the initial acquisition, with an option to purchase an ...
(Date:7/31/2020)... ... 2020 , ... R3 Stem Cell International is now offering patients the opportunity ... cells total, patients may choose which extremities they would like treated. , Several studies ... Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with ...
Breaking Biology Technology:
(Date:9/3/2020)... ... 2020 , ... Litmus Health , the research-ready infrastructure ... the company’s security practices has been completed. The assessment deemed Litmus infrastructure to ... reviewed Litmus’ processes and systems, assessing them to see whether they adhere to ...
(Date:8/26/2020)... (PRWEB) , ... August 25, ... ... clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex ... enrolment in its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic ...
(Date:8/26/2020)... ... ... Modality Solutions, a biopharmaceutical cold chain validation engineering firm, is pleased to ... most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions made the Inc. ... growth of 71 percent. , The Inc. 5000 list represents a unique look ...
Breaking Biology News(10 mins):